Attached files
| file | filename |
|---|---|
| 10-Q - ONCOVISTA INNOVATIVE THERAPIES, INC | v193872_10-q.htm |
| EX-31.2 - ONCOVISTA INNOVATIVE THERAPIES, INC | v193872_ex31-2.htm |
| EX-31.1 - ONCOVISTA INNOVATIVE THERAPIES, INC | v193872_ex31-1.htm |
CERTIFICATION
PURSUANT TO
18 U.S.C.
SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Quarterly Report on Form 10-Q of OncoVista Innovative
Therapies, Inc. (the "Company") for the period ended June 30, 2010 filed with
the Securities and Exchange Commission (the "Report"), I, Alexander L. Weis,
Chief Executive Officer and Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:
(1) The
Report fully complies with the requirements of Section 13(a) of the Securities
Exchange Act of 1934; and
(2)
The information contained in the Report
fairly presents, in all material respects, the
consolidated financial condition of the Company as of the
dates presented and consolidated results of operations of the Company
for the periods presented.
Dated:
August 16, 2010
By:
/s/ Alexander L. Weis, Ph.D.
Alexander
L. Weis, Ph.D.
Chief
Executive and Financial Officer
This
certification has been furnished solely pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
A signed
original of this written statement required by Section 906 has been provided to
the Company and will be retained by the Company and furnished to the Securities
and Exchange Commission or its staff upon request.
- 27 -